Menstrual blood, often discarded as waste, is now revealing crucial insights into women’s reproductive health. Thanks to advancements pioneered by companies like NextGen Jane, tampons are becoming valuable tools for noninvasive diagnostics, potentially changing how conditions like endometriosis and infertility are detected and monitored.
- Menstrual blood reveals unique health biomarkers
- Noninvasive testing for conditions like endometriosis is advancing
- Clinical studies and startups are expanding menstrual blood diagnostics
What happened
Ridhi Tariyal, after being denied a fertility test she knew was available, turned menstrual blood into a potent source for medical testing. Her company, NextGen Jane, developed patented methods to extract and analyze blood from tampons, enabling women to send in samples from home without invasive procedures. This innovation has led to more than 90% accurate detection of endometriosis, a condition that affects one in ten women but often goes undiagnosed for years.
Why it feels good
This shift toward menstrual blood as a diagnostic tool empowers women by providing convenient, painless testing options that utilize the body’s natural processes. It challenges long-standing taboos around menstruation and transforms what was once just biological waste into a vital source of health information that can enhance care and early diagnosis.
Moreover, these innovations respond to real frustrations many women face with traditional health care—delayed diagnoses, invasive testing, and barriers to accessing reproductive health data. By making testing more accessible and less intimidating, millions of women can better understand and manage their reproductive health with confidence and ease.
What to enjoy or watch next
NextGen Jane continues its research, expanding infertility-focused studies to enhance its noninvasive testing platforms. Keep an eye on clinical trials like Northwell Health’s ROSE, which aims to improve endometriosis diagnosis, a condition notoriously underestimated and underdiagnosed worldwide.
Also worth watching are innovations from entrepreneurs like Sara Naseri, whose menstrual pad technology received FDA clearance for diabetes monitoring. As awareness grows and these technologies mature, menstrual blood testing could soon become a routine part of healthcare—not just for reproductive health but for a range of conditions—helping women everywhere achieve better health outcomes.